Table 1. Baseline characteristics were balanced between GnRH-a treatment group and GnRH-a-free group.
| Characteristics | GnRH-a treatment, n=45 cycles | GnRH-a-free, n=218 cycles | P value |
|---|---|---|---|
| Maternal age (years), mean ± SD | 33.5±3.7 | 34.8±4.7 | 0.087 |
| Paternal age (years), mean ± SD | 35.2±5.2 | 36.7±6.0 | 0.121 |
| Infertility type (%) | 0.098 | ||
| Primary infertility | 23/45 (51.1%) | 82/218 (37.6%) | |
| Secondary infertility | 22/45 (48.9%) | 136/218 (62.4%) | |
| Duration of infertility (years), median (IQR) | 3 (2, 6) | 4 (2, 8) | 0.289 |
| Gravidity times, median (IQR) | 0 (0, 2) | 1 (0, 2) | 0.265 |
| Parity times, median (IQR) | 0 (0, 0) | 0 (0, 0) | 0.093 |
| Uterine volume (cm3), mean ± SD | 81.3±13.1 | 78.9±11.7 | 0.220 |
| Adenomyotic lesions (%) | 0.145 | ||
| Diffuse | 31/45 (68.9%) | 172/218 (78.9%) | |
| Focal | 14/45 (31.1%) | 46/218 (21.1%) | |
| BMI (kg/m2), mean ± SD | 23.9±3.9 | 23.0±4.1 | 0.184 |
| AMH (ng/mL), mean ± SD | 3.36±2.6 | 3.50±2.9 | 0.873 |
| FSH (mIU/mL), mean ± SD | 6.52±1.5 | 6.53±2.2 | 0.985 |
| Endometrial thickness (mm), mean ± SD | 10.0±2.2 | 10.0±1.7 | 0.964 |
| No. of embryos transferred, mean ± SD | 1.48±0.6 | 1.49±0.6 | 0.852 |
| Transferred embryo (%) | 0.475 | ||
| Cleavage embryo | 11/45 (24.4%) | 68/218 (31.2%) | |
| Blastocyst | 34/45 (75.6%) | 150/218 (68.8%) | |
| Clinical pregnancy rate (%) | 24/45 (53.3%) | 86/218 (39.4%) | 0.098* |
| Miscarriage rate (%) | 3/24 (12.5%) | 32/86 (37.2%) | 0.025* |
| Live birth rate (%) | 21/45 (46.7%) | 54/218 (24.8%) | 0.006* |
*, P value of univariate analysis. GnRH-a, gonadotrophin-releasing hormone agonist; SD, standard deviation; IQR, interquartile range; BMI, body mass index; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone.